Metabolomics for early-stage lung adenocarcinoma: diagnostic biomarker screening.

ABSTRACT:

Objective

This study aimed to identify specific metabolic markers in the blood that can diagnose early-stage lung adenocarcinoma.

Methods

An untargeted metabolomics study was performed, and the participants were divided into four groups: early-stage lung adenocarcinoma group (E-LUAD; n = 21), healthy control group (HC, n = 17), non-cancerous lung disease group (NCC; n = 17), and advanced lung adenocarcinoma group (A-LUAD; n = 25). Plasma metabolite levels that differed in the E-LUAD group compared to the other three groups were identified via liquid chromatography-mass spectrometry (LC-MS). Principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) were performed at metaX for statistical analysis. A Venn diagram was constructed to identify ov

SUBMITTER: Sun D 

PROVIDER: S-EPMC11932905 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature